InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) Holds Key Meetings, Advances Product at Frankfurt CPHI Conference
November 21, 2022
BioNxt Solution (CSE: BNXT) (OTC: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery and diagnostic and new active pharmaceutical ingredient investment opportunities, is reporting on its participation at the CPHI pharma conference in Frankfurt, Germany. Earlier this month, BioNxt management attended the event, which is the largest pharma conference in the world; […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Changes Name to BioNxt Solutions Inc.
November 10, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has announced a name change. According to the company, effective next Monday, Nov. 14, 2022, the company’s name will change from XPhyto Therapeutics Corp. to BioNxt Solutions Inc. Along with the name change, the company’s trading symbol will change to BNXT from XPHY. The company will continue to focus […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Major Milestone on Path to Commercialization of Lead Product
October 18, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today reported the results of its Rotigotine transdermal (“TDS”) patch human skin cadaver study and dissolution data. The company’s Rotigotine patch is based on the TDS platform technology developed by Vektor Pharma TF GmbH, its wholly owned German subsidiary. Further to its product update on Oct. 11, […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Completion of Rotigotine TDS Patch Study
October 11, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today provided a product development report on its Rotigotine transdermal (“TDS”) patch. According to the update, the company’s Rotigotine patch is based on TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH. The company has, over the past 90 days, been focused […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks LOI to Identify Manufacturing, Strategic Business Opportunities
October 5, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has signed a nonbinding letter of intent (“LOI”) with a U.S.-based thin film manufacturing firm. The collaboration between the two companies will focus on evaluating potential business synergies for manufacturing, import/export, distribution and product development. According to the announcement, the manufacturing firm has a state-of-the-art, FDA-certified pharma production […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE:4XT) Announces Patent Application for Novel Psychedelic Compound Library
September 20, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE:4XT) has filed a patent application covering a significant library of novel psychedelic compounds. According to the announcement, each compound included in the filing is designed to provide specific alterations in their respective biopharmaceutical properties. The company noted that it expects the global psychedelic drugs market to see significant market […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Exploring Expanded Application of ODF Screening Tests
July 18, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE:4XT) is taking a close look at a significant potential market for its oral dissolvable (“ODF”) biosensor screening tests for oral inflammation. According to the company, some buprenorphine medicines prescribed to treat opioid use disorder (“OUD”) and pain have been linked to serious oral health problems that necessitate medical intervention. […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Congratulates Dr. Raimar Loebenberg as Recipient of 2022 CSPS Award
June 27, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today congratulated Prof. Dr. Raimar Loebenberg as the 2022 recipient of the CSPS Award of Leadership in Canadian Pharmaceutical Sciences. Dr. Loebenberg, a director and founder of XPhyto, is a professor in the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta (“UoA”) and the founder and […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Expands European Team to Add Pharmaceutical Manufacturing Expert
June 8, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that Dr. Florian A. Sahr has joined its European operations as head of project management. A German-born and internationally trained leader in formulation, technology transfer and new-product manufacturing, Dr. Sahr has a strong track record of drug development. This includes transdermal (“TDS”) and oral dissolvable […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Reports Positive Results of Rotigotine Transdermal Patch Study
May 9, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released an update on its Rotigotine transdermal (“TDS”) patch. The patch is based on the TDS platform technology developed by the company’s wholly owned German subsidiary, Vektor Pharma TF GmbH. The company noted that it had […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Market, Product Development of Key Biosensor
April 12, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released a market and product development report. The report focused on XPhyto’s sublingual oral dissolvable film (“ODF”) biosensor development pipeline, which include the company’s oral dissolvable products. These products are based on proprietary ODF platform technology […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Update on Rotigotine Transdermal Patch Development
April 4, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, is reporting on the market and product development of its Rotigotine transdermal (“TDS”) patch, which is designed for the treatment of Parkinson’s disease (“PD”) and restless legs syndrome (“RLS”). XPhyto’s Rotigotine patch features the TDS platform technology […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Closes First Tranche of Private Placement
April 1, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that, further to its news release of March 25, 2022, it has closed the first tranche of its private placement. According to the update, the company issued 1,250,000 common […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Updates on Psychedelic Medicine Programs Progess, Novel Compounds Milestone
February 22, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released an update regarding its wholly owned subsidiary XPhyto Laboratories Inc. XPhyto Labs’ psychedelic medicine programs are focused on a multipronged approach to psychedelic medicine and include GMP (“GMP”) drug synthesis, proprietary drug-delivery systems, novel psychedelic […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update Regarding Its Three Primary Business Divisions
February 8, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today issued an update as part of its product development, commercialization and revenue growth strategy. The company reported on its three business divisions and wholly owned subsidiaries, which include Vektor Pharma […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces New Covid-ID Lab Sales Contracts
February 1, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has executed Covid-ID Lab sales contracts with Corona Testzentren (Digitallife), powered by digitallifecare GmbH, Germany. According to the announcement, Digitallife runs several coronavirus test centers south of Stuttgart, Germany, servicing some 75,000 area residents. XPhyto noted that […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Integration of 3a-diagnostics GmbH
January 24, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today provided an update on the integration of 3a-diagnostics GmbH (“3a”) into XPhyto’s German operations. According to the update, the acquisition of 3a, announced Dec. 6, 2021, is a primary driver […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Appoints European Head of Sales
January 18, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has named Drahoslav Zdarek as its head of sales in Europe. According to the announcement, Zdarek will focus on developing distribution, sales and marketing of the company’s products; top on the list of assignments Zdarek will be […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Czech Republic Distribution Deal, Announces Rollout Plan for Additional European Territories
January 13, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has signed a distribution agreement with TechUnit s.r.o. (Limited). TechUnit is a privately owned company focused on medical product distribution, advertisement and promotion. The agreement outlines parameters for the distribution of XYPHY’s Covid-ID Lab in the Czech […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Strategic Appointments
January 10, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products, including for the detection of COVID-19. Roland Spleiss, a seasoned commercial […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces January 2022 Commencement of Epilepsy Clinical Trial
December 15, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today provided an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved in the planning and preparation for the pending pilot trial, the company announced that […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Completes Transformative Step in Commercial Strategy with 3a Acquisition
December 6, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has completed its acquisition of 3a-diagnostics GmbH (“3a”), first announced July 20, 2021. “The strategic acquisition of 3a is a transformative step in XPhyto’s commercial strategy,” said Peter Damouni, XPhyto director. […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Appoints New CFO
November 22, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has named a new chief financial officer: Joseph Meagher. A chartered professional accountant (“CPA, CA”) and a chartered director, Meagher most recently worked at Defence Therapeutics Corp, a publicly traded biotechnology company engineering next-generation vaccines and anti-body […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) Featured in Coverage of Investor Summit Group’s Q4 Virtual Event
November 10, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Shares Drug-Development Update
October 12, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released updated information regarding its drug formulation and development focus. The company is continuing its focus on advancing multiple generic and hybrid-generic programs for neurotherapeutics. Highlights of the update include that planning for XPhyto’s Rotigotine transdermal […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Extends Agreements with Partners
October 11, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has extended its investor relations consulting agreement with Knox Communications Inc. (“KCI”) and M. Davis & Associates Capital Inc. The agreements are designed to support XPhyto in its marketing and investor communications activities. The […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference
September 27, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug diagnostics, delivery and new active pharmaceutical ingredient investment opportunities, including: rapid, low-cost infectious disease test (EU approved rapid PCR test) and oral health screening tests; precision transdermal and oral dissolvable drug formulations; and standardization of emerging active pharmaceutical ingredients for neurological applications, including […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Proprietary COVID-19 PCR Test COVID-ID Lab Launch Deemed a Success
September 8, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that the market launch of its 25-minute COVID-19 PCR Test COVID-ID Lab has been a success. The company unveiled the project at test centers in Berlin, and XPhyto reports the successfully optimization of operational procedures and […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Registers First Oral Disease Biosensor for Commercialization
August 30, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has registered its first biosensor test in oral inflammation with German authorities. The company registered the easy, at-home, self-check test with the assistance of its partner and acquisition target, 3a-diagnostics GmbH (“3a”). The biosensor […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in “Forbes” Article Discussing Mescaline
August 13, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, was featured in an article titled “Is Mescaline a Key Component in the Future of Medicine? XPhyto Aims to Find Out.” The article notes that mescaline (3,4,5-trimethoxyphenethylamine), the magical alkaloid found in the peyote cactus and similar […]
InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates
July 28, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Definitive Agreement to Acquire 3a-Diagnostics
July 20, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, has signed a definitive agreement to acquire its exclusive diagnostics development partner 3a-diagnostics GmbH, Frickenhausen, Germany. Per the terms of the definitive agreement, XPhyto will acquire all outstanding shares of 3a for EUR 400,000, to be paid immediately, and EUR 3.5 million, to […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising
July 19, 2021
XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting […]
InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Covid-ID Lab Filling Existing Market Gap
July 13, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25. The company is likely to benefit from the country’s regulatory requirements and the government’s […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy
July 12, 2021
XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes XPhyto plans to capitalize on the rapid test market, projected to reach […]
XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track
June 30, 2021
XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significant milestone for the program Mescaline will form a critical component in XPhyto’s psychedelic medicine program […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Finalizes Supply Agreement with Two German Companies for COVID-19 PCR Test
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberries GmbH. The two companies run 10 COVID-19 test centers in Berlin. The supply agreement outlines […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Advancing Rotigotine Development Program for Parkinson’s
June 22, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Latest Episode of Bell2Bell Podcast
June 17, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, was featured in the Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director Hugh Rogers joined the latest episode to offer an operational update and discuss the company’s […]
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO of XPhyto Therapeutics Corp.
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of an exclusive The Bell2Bell Podcast interview with Hugh Rogers, CEO and Director of life sciences technology accelerator XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT). During […]